Diabetes, a leading cause of nephropathy, retinopathy, neuropathy, and coronary and peripheral vascular disease, is the third most prevalent severe chronic disease of childhood in the U.S. (1). People with diabetes diagnosed before the age of 20 years have a life expectancy that is 15–27 years shorter than people without diabetes (1), although prospective data show improvements in mortality for those diagnosed in more recent years (2). Until only a decade ago, diabetes diagnosed in children and adolescents was almost entirely considered to be type 1 diabetes, most often due to the autoimmune destruction of the β-cells of the pancreas leading to an absolute deficiency of insulin. Diabetes in children and adolescents is now viewed as a complex disorder with heterogeneity in its pathogenesis, clinical presentation, and clinical outcome. The occurrence of what appears clinically to be type 2 diabetes in youth, particularly overweight minority youth, has been documented in several studies.
The SEARCH for Diabetes in Youth Study, funded by the Centers for Disease Control and Prevention, Division of Diabetes Translation, with support from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, began in 2000 with an overarching objective to describe childhood diabetes as it occurs among the five major race and ethnic groups in the U.S. These groups include non-Hispanic white, Hispanic, Asian/Pacific Islander, African American, and American Indian. Key aims of the study with a focus on race and ethnicity are the following:
To estimate the prevalence and incidence of physician-diagnosed diabetes in youth aged <20 years by age, sex, race/ethnicity, and diabetes type; and
To characterize key risk factors for diabetes complications, according to race/ethnicity and diabetes type.
As previously published by the SEARCH study, both type 1 and type 2 diabetes occur in each of the five major race/ethnic groups under surveillance (3,4). These publications, as well as other publications and presentations from the SEARCH study, have reported on findings related to critical aspects of diabetes in youth and have included data on race/ethnicity to the extent deemed appropriate. In this Diabetes Care supplement, we provide a set of five articles, each devoted to one of the five race/ethnic groups. These articles were designed to provide a comprehensive picture of the face of diabetes in the race/ethnic group of interest and to highlight important aspects of the epidemiologic, biochemical, quality-of-care, social, and behavioral aspects of diabetes in these youth. The articles also report on key findings relevant to the experience of diabetes that have not been published to date and that may advance our understanding of diabetes and generate new research. Here, we present the general philosophy of the SEARCH study with regard to race and ethnicity and highlight content of the five papers included in this supplement.
The constructs of race and ethnicity in biomedical research have been hotly debated in recent years (5–8), with concerns raised regarding the meaning of race in a biologic or genetic sense versus social and cultural aspects of race and ethnic self-identification. Some researchers have promoted a “race-neutral approach” in the absence of clear evidence for biological or genetic significance (9,10). However, particularly in the area of diabetes, marked differences in health outcomes and risk factors for health outcomes have been identified for subgroups of individuals defined according to U.S. Census–based self-identification of race and ethnicity. Accordingly, many researchers promote use of self-identified race and ethnicity as the most valid measure for most types of epidemiologic studies (11,12). This is the approach used by the SEARCH study. Although the U.S. Census accommodates reporting of multiple races, in the SEARCH study we did not have sufficient participant numbers to allow evaluation of separate categories of reported multiple race groups. Other than the specific combination of Asian and Pacific Islander who are included in the Asian and Pacific Islander article, only 5% of those who reported Hispanic ethnicity and 4% of non-Hispanic individuals selected more than one race. Rather than exclude these individuals, we utilized the National Center for Health Statistics plurality approach, in which data from a study designed to address multiple-race reporting was used to determine which single-race category should be assigned for specific combinations of multiple races reported (13).
For each of the five articles in this supplement, estimates of prevalence, incidence, and selected demographic and clinical characteristics of youth with diabetes are reported. Because diabetes is unique in many ways across the race/ethnic groups, each article presents additional data accordingly and provides discussion points as appropriate. A preview of the areas of focus for each article is as follows:
Non-Hispanic whites
Incidence of type 1 diabetes is compared with results from other studies conducted around the world in other white populations.
Characteristics of non-Hispanic white youth with type 2 diabetes, albeit quite rare in this group, are described.
African Americans
Type 1 diabetes in African American adolescents, generally not the focus in recent literature, is described.
Prevalence of poor metabolic status and unhealthy lifestyle behaviors for African American youth with either type 1 or type 2 diabetes is highlighted.
Key demographic factors related to socioeconomic status are considered.
Hispanics
The burden of diabetes related to both type 1 and type 2 diabetes in Hispanic youth is described and differences by sex are reported.
Poor glycemic control and adverse cardiovascular disease risk profile in youth with both type 1 and type 2 diabetes are highlighted.
Asians and Pacific Islanders
Characteristics of diabetes, including weight status, are compared across subgroups of Asian/Pacific Islanders and those who are of both Asian and Pacific Island descent.
Navajo
The occurrence of type 1 diabetes and the heavy burden of type 2 diabetes among Navajo youth is described.
Poor glycemic control, adverse cardiovascular disease risk factors, and unhealthy health behaviors are described.
The SEARCH study is uniquely positioned to provide the picture of the many faces of childhood diabetes, collected under a standardized protocol, in this large cohort of youth from five major racial and ethnic groups in the U.S. Because the goal of this supplement is to provide information regarding the burden of childhood diabetes from a public health surveillance perspective (hence reporting of the prevalence and incidence data) and to describe childhood diabetes in a clinically relevant manner, we have chosen to present data according to the type of diabetes as diagnosed by the treating physician. We have previously shown that using this approach results in grouping of youth with a clinical diagnosis of type 1 diabetes who are much more likely to have a positive diabetes autoantibody, with much lower fasting C-peptide concentrations, than youth with a clinical diagnosis of type 2 diabetes (3). Table 1 shows the number of youth with clinically diagnosed type 1 and type 2 diabetes, according to race/ethnicity, who are included in analyses presented in this supplement.
The SEARCH study methods have been published previously (14), and further details regarding the protocol are available online at www.searchfordiabetes.org. To provide valid information on prevalence and incidence, case ascertainment must be high. Based on capture-recapture analyses, completeness of ascertainment was >90% for prevalence and incidence (3,4). We have recently systematically evaluated response rates to the SEARCH study in-person research visit (15) and reported that older, nonwhite individuals and those with type 2 diabetes were less likely to attend the research visit than younger, non-Hispanic white individuals and those with type 1 diabetes. However, in a previous report from the SEARCH study, estimating prevalence of elevated albumin-to-creatinine ratio in SEARCH study youth with type 1 and type 2 diabetes, we provided evidence that selection bias did not impact on the prevalence estimate of this important clinical outcome (16).
The SEARCH study is ongoing with collection of prospective data in a subset of the cohort and ongoing ascertainment of incident cases and related data collection. It is anticipated that the study in general, and this supplement, will inspire new ideas for clinical or public health practice and will inspire new research toward advancing our understanding of diabetes and its complications in youth.
. | Clinical type 1 diabetes (aged 0–19 years at diagnosis) . | . | Clinical type 2 diabetes (aged 10–19 years at diagnosis) . | . | ||
---|---|---|---|---|---|---|
. | Cases for prevalence or incidence estimation . | Subset for clinical characteristics . | Cases for prevalence or incidence estimation . | Subset for clinical characteristics . | ||
Prevalent 2001 | ||||||
Non-Hispanic white | 4,045 | 1,691 | 198 | 37 | ||
African American | 490 | 178 | 202 | 77 | ||
Hispanic | 638 | 290 | 143 | 41 | ||
Asian/Pacific Islander | 167 | 95 | 88 | 17 | ||
Navajo | 18 | 12 | 74 | 40 | ||
All prevalent cases | 5,359 | 2,266 | 705 | 212 | ||
Incident 2002–2005 | ||||||
Non-Hispanic white | 2,800 | 1,692 | 241 | 78 | ||
African American | 450 | 258 | 298 | 135 | ||
Hispanic | 448 | 261 | 187 | 86 | ||
Asian/Pacific Islander | 107 | 82 | 103 | 51 | ||
Navajo | 10 | 5 | 56 | 26 | ||
All incident cases | 3,815 | 2,298 | 885 | 376 | ||
Total cases | 9,174 | 4,564 | 1,590 | 588 |
. | Clinical type 1 diabetes (aged 0–19 years at diagnosis) . | . | Clinical type 2 diabetes (aged 10–19 years at diagnosis) . | . | ||
---|---|---|---|---|---|---|
. | Cases for prevalence or incidence estimation . | Subset for clinical characteristics . | Cases for prevalence or incidence estimation . | Subset for clinical characteristics . | ||
Prevalent 2001 | ||||||
Non-Hispanic white | 4,045 | 1,691 | 198 | 37 | ||
African American | 490 | 178 | 202 | 77 | ||
Hispanic | 638 | 290 | 143 | 41 | ||
Asian/Pacific Islander | 167 | 95 | 88 | 17 | ||
Navajo | 18 | 12 | 74 | 40 | ||
All prevalent cases | 5,359 | 2,266 | 705 | 212 | ||
Incident 2002–2005 | ||||||
Non-Hispanic white | 2,800 | 1,692 | 241 | 78 | ||
African American | 450 | 258 | 298 | 135 | ||
Hispanic | 448 | 261 | 187 | 86 | ||
Asian/Pacific Islander | 107 | 82 | 103 | 51 | ||
Navajo | 10 | 5 | 56 | 26 | ||
All incident cases | 3,815 | 2,298 | 885 | 376 | ||
Total cases | 9,174 | 4,564 | 1,590 | 588 |
Data are n.
Article Information
The SEARCH for Diabetes in Youth Study is funded by the Centers for Disease Control and Prevention (PA no. 00097 and DP-05-069) and is supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site contract numbers are as follows: Kaiser Permanente Southern California (U01 DP000246), the University of Colorado Health Sciences Center (U01 DP000247), the Pacific Health Research Institute (U01 DP000245), Children's Hospital Medical Center (Cincinnati, Ohio) (U01 DP000248), the University of North Carolina at Chapel Hill (U01 DP000254), the University of Washington School of Medicine (U01 DP000244), and Wake Forest University School of Medicine (U01 DP000250). The authors acknowledge the involvement of general clinical research centers at the following institutions in the SEARCH study: the Medical University of South Carolina (grant no. M01 RR01070), Cincinnati Children's Hospital (grant no. M01 RR08084), Children's Hospital and Regional Medical Center and the University of Washington School of Medicine (grant no. M01RR00037 and M01RR001271), and the Colorado Pediatric General Clinical Research Center (grant no. M01 RR00069).
No potential conflicts of interest relevant to this article were reported.
The SEARCH study is indebted to the many youth and their families and their health care providers, whose participation made this study possible.
The writing group for this manuscript acknowledges the contributions of the following individuals to the SEARCH study: California: Jean M. Lawrence, ScD, MPH, MSSA; Ann K. Kershnar, MD; Kristi Reynolds, PhD, MPH; and Marlene Y. Gonzalez, MPH, for Kaiser Permanente Southern California; David J. Pettitt, MD, for the Sansum Diabetes Research Institute; and Diana B. Petitti, MD, MPH, for the University of Southern California. Colorado: Dana Dabelea, MD, PhD; Richard F. Hamman, MD, DrPH; and Lisa Testaverde, MS, for the Department of Preventive Medicine and Biometrics, University of Colorado Denver; Georgeanna J. Klingensmith, MD, and Marian J. Rewers, MD, PhD, for the Barbara Davis Center for Childhood Diabetes; Stephen Daniels, MD, PhD, Department of Pediatrics and Children's Hospital; Clifford A. Bloch, MD, for the Pediatric Endocrine Associates; Jonathan Krakoff, MD, and Peter H. Bennett, MD, FRCP, for the National Institute of Diabetes and Digestive and Kidney Diseases Pima Indian Study; Joquetta A. DeGroat, BA, for the Navajo Area Indian Health Prevention Program; and Teresa Coons, PhD, for the St. Mary's Hospital Grand Junction. Hawaii: Beatriz L. Rodriguez, MD, PhD; Beth Waitzfelder, PhD; Wilfred Fujimoto, MD; J. David Curb, MD; Fiona Kennedy, RN; Greg Uramoto, MD; Sorrell Waxman, MD; Teresa Hillier, MD; and Richard Chung, MD, for the Pacific Health Research Institute. Ohio: Lawrence M. Dolan, MD; Michael Seid, PhD; Nancy Crimmins, MD; and Debra A. Standiford, MSN, CNP, for the Cincinnati Children's Hospital Medical Center. South Carolina: Elizabeth J. Mayer-Davis, PhD, and Joan Thomas MS, RD, for the University of North Carolina, Chapel Hill; Angela D. Liese, PhD, MPH; Robert McKeown, PhD; Robert R. Moran, PhD; Deborah Truell, RN, CDE; Gladys Gaillard-McBride, RN, CFNP; Deborah Lawler, MT (ASCP); and Malaka Jackson, MD, for the University of South Carolina; Lynne Hartel, MA; Yaw Appiagyei-Dankah, MD; and Lyndon Key, MD, for the Medical University of South Carolina; Sheree Mejia, RN; James Amrhein, MD; and Kent Reifschneider, MD, for Greenville Hospital Systems; Pam Clark, MD, for McLeod Pediatric Subspecialists; Mark Parker, MD, for Pediatric Endocrinology & Diabetes Specialists, Charlotte, NC; Pediatric Endocrinology at the Medical College of Georgia; and I. David Schwartz, MD. Washington: Catherine Pihoker, MD; Lisa Gilliam, MD, PhD; Irl Hirsch, MD; Lenna L. Liu, MD, MPH; Carolyn Paris, MD, MPH; and Dimitri Christakis, MD, MPH, for the University of Washington; Beth Loots, MPH, MSW; Joyce Yi, PhD; Stacey Bryant, RN; Michelle Sadler-Greever, RN, CDE; Rebecca O'Connor, RN; Ellen Braun-Kelly, BS; Amber Sexton, BS; and Corinne Shubin, BA, for the Seattle Children's Hospital and Regional Medical Center; and Carla Greenbaum, MD, for Benaroya Research Institute. Centers for Disease Control and Prevention: Giuseppina Imperatore, MD, PhD; Desmond E. Williams, MD, PhD; Michael M. Engelgau, MD; Henry S. Kahn, MD; K.M Venkat Narayan, MD, MPH; and Bernice Moore, MBA. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health: Barbara Linder, MD, PhD. Central Laboratory (University of Washington): Santica M. Marcovina, PhD, ScD; Vinod P. Gaur, PhD; and Kathy Gadbois. Coordinating Center (Wake Forest University School of Medicine): Ronny Bell, PhD, MS; Ralph D'Agostino, Jr., PhD; Douglas Case, PhD; Timothy Morgan, PhD; Michelle J. Naughton, PhD; Susan Vestal, BS; Gena Hargis, MPH; Andrea Ruggiero, MS; Cralen Davis, MS; Jeanette Stafford, MS; and Jennifer Beyer, MS.
References
The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Diseases.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.